Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

FDA rejects PTC's application for muscular dystrophy drug

FDA rejects PTC's application for muscular dystrophy drug Translarna is intended to treat DMD caused by nonsense mutations in the dystrophin gene and works via a slightly different mechanism to other DMD therapies coming through the pipeline, including

Deal Watch October 2015

Deal Watch October 2015 This month's deal between Merck Serono (Merck KGaA) and BioMarin is a good example of this approach. ... Acquisition - company. 580. Merck Serono/ BioMarin. Kuvan and pegvaliase (Kuvan marketed; pegvaliase p3).

FDA panel rejects BioMarin's muscular dystrophy drug

FDA panel rejects BioMarin's muscular dystrophy drug Fails to convince committee of its safety and efficacy. BioMarin has failed to convince an FDA advisory committee that its Kyndrisa therapy for Duchenne muscular dystrophy (DMD) is either safe or ... BioMarin acquired rights to drisapersen via its $840m

BioMarin's real world data sways NICE on orphan drug Vimizim

BioMarin's real world data sways NICE on orphan drug Vimizim Rare genetic disorder treatment recommended in final draft guidance. NICE has issued final draft guidance recommending BioMarin Pharma's Vimizim (elosulfase alfa) for the treatment of the rare genetic disorder Morquio

Pharma deals in August 2015

Pharma deals in August 2015 Licence. 700. BioMarin. Medivation. Talazoparib a PARP inhibitor in P3 for BRCA mutated breast cancer.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics